Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Alessandra Tosolini et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret O’Donnell, Ndiya Ogba, Martin S. Tallman et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 655
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid LeukemiaYi‐Bin Chen, Robert J. Soiffer, Shuli Li et al.|Biology of Blood and Marrow Transplantation|2014Cited by 234
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i> <scp>FLT</scp> 3 </i> ‐ <scp>ITD</scp> acute myeloid leukaemia in first complete remissionAndrew M. Brunner, Yi‐Bin Chen, Shuli Li et al.|British Journal of Haematology|2016Cited by 174